**Name of Journal: *World Journal of Stem Cells***

**Manuscript NO: 35363**

**Manuscript Type:** **Minireviews**

**Tracing and targeting cancer stem cells: New venture for personalized molecular cancer therapy**

Radpour R. Cellular and molecular methods to trace and target CSCs

**Ramin Radpour**

**Ramin Radpour,** Tumor Immunology and Cancer Stem Cells, Inselspital, Bern University Hospital, Department for BioMedical Research, University of Bern, 3008 Bern, Switzerland

**ORCID number:** Ramin Radpour ([0000-0002-5632-7833](http://orcid.org/0000-0002-5632-7833" \t "_blank)).

**Author contributions:** Radpour R wrote the paper.

**Conflict-of-interest statement:** There is no conflict of interest.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Manuscript source:** Unsolicited manuscript

**Correspondence to: Ramin Radpour, MSc, PhD,** Tumor Immunology and Cancer Stem Cells, Inselspital, Bern University Hospital, Department for BioMedical Research, University of Bern, Murtenstrasse 35, 3008 Bern, Switzerland. ramin.radpour@dkf.unibe.ch

**Telephone:** +41-31-6320956

**Fax:** +41-31-6323297

**Received:** July 10, 2017

**Peer-review started:** July 14, 2017

**First decision:** August 7, 2017

**Revised:** August 14, 2017

**Accepted:** September 3, 2017

**Article in press:**

**Published online:**

**Abstract**

Tumors consist of a mixture of heterogeneous cell types. Cancer stem cells (CSCs) are a minor sub-population within the bulk cancer fraction which has been found to reconstitute and propagate the disease and to be frequently resistant to chemotherapy, irradiation, cytotoxic drugs and probably also against immune attack. CSCs are considered as the seeds of tumor recurrence, driving force of tumorigenesis and metastases. This underlines the urgent need for innovative methods to identify and target CSCs. However, the role and existence of CSCs in therapy resistance and cancer recurrence remains a topic of intense debate. The underlying biological properties of the tumor stem cells are extremely dependent on numerous signals, and the targeted inhibition of these stem cell signaling pathways is one of the promising approaches of the new antitumor therapy approaches. This perspective review article summarizes the novel methods of tracing CSCs and discusses the hallmarks of CSC identification influenced by the microenvironment or by having imperfect detection markers. In addition, explains the known molecular mechanisms of therapy resistance in CSCs as reliable and clinically predictive markers that could enable the use of new targeted antitumor therapy in the sense of personalized medicine.

**Key words:** Cancer stem cells; Cancer recurrence; Cancer therapy; Combination therapy; Chemotherapy; Radiation therapy; Immunotherapy

**© The Author(s) 2017.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip****:** Cancer stem cells (CSCs) are small subpopulation of the tumor that can survive from conventional treatment, scape from the immune system and can cause recurrence of cancer disease. Therefore, any attempt in detection and selective therapeutic targeting of CSCs will ultimately lead to better cancer treatments and can play an important role in reducing the cancer related mortalities. This review highlights the trends and approaches in CSC tracing, isolating, characterizing and targeting, which are key strategies for a novel personalized molecular cancer therapy.

Radpour R. Tracing and targeting cancer stem cells: New venture for personalized molecular cancer therapy. *World J Stem Cells* 2017; In press

**INTRODUCTION**

Cancer originates from deregulation of growth and resistance to apoptosis of transformed cells that acquire proliferative and metastatic capacity. While only a few genetic and epigenetic alterations can initiate the malignant transformation of healthy cells, clinically visible tumors are extraordinarily complex structures with cancer cells displaying a large number of mutations and altered gene expression[[1](#_ENREF_1)]. The hierarchical model of tumor organization represents a similar, albeit distorted, arrangement of the tumor cells, as are their tissues of origin. The stem cell population is positioned at the top of the cell hierarchy and has the ability to self-renew and multilineage differentiate to progenitors or differentiated cell types whose proliferation capacity is restricted[[2](#_ENREF_2),[3](#_ENREF_3)].

The theory of the cancer stem cell (CSC) was postulated in the 1970s and was confirmed experimentally by the isolation of tumor-initiating cells using cellular/molecular biomarkers that allowed the isolation of CSCs in acute myeloid leukemia[[4](#_ENREF_4)]. Further, CSC has been demonstrated in a variety of solid tumors such as tumors in brain, colorectal, head and neck, liver, lung, mammary glands, pancreatic prostate carcinomas, melanoma and hematopoietic malignancies (*e.g*., myeloid or lymphoid leukemia)[[5-7](#_ENREF_5)]. Cell lines derived from these tumors also contain CSCs and tumor precursor cells, which represent a promising model for cancer stem cell research[[1](#_ENREF_1)]. The functional characterization of CSCs revealed that these cells represent a small subpopulation of the tumor that can survive from conventional treatment, scape from the immune system and therefore can cause recurrence of cancer disease. Therefore, CSCs are driving force of tumorigenesis and metastases (Figure 1). According to the concept of a stem cell, it is assumed that even a few surviving CSCs after tumor therapy, is sufficient to form a new tumor[[8](#_ENREF_8)].

In each cancer cell clone, which is characterized by harboring different combinations of mutations or genetic alterations, the processes of self-renewal, and differentiation occur differently based on the type of genetic lesions[[9](#_ENREF_9)]. Nevertheless, significant similarities between normal and tumorigenic, experimentally identified stem cells could be expected. Both stem cell types (normal or cancerous) are rarely active, dependent on a specific microenvironment (so-called “stem cell-niche”) and have a number of self-protection mechanisms[[2](#_ENREF_2)]. This niche enables a dynamic interaction between stem cells and surrounding cells including immune cells (“immune-niche”), cytokines and chemokines that regulates maintenance, quiescence, self-renewal and differentiation of stem cells to provide an optimal stem cell-supporting setting. What contributes to formation of the niche for tumor stem cells is the subject of intensive research[[10](#_ENREF_10)]. Normal stem cells are more microenvironment dependent in order to get dynamic input to balance between activation and differentiation or self-renewal and quiescence “extrinsic factors”[[11](#_ENREF_11),[12](#_ENREF_12)]. Although CSCs can represent more autonomous regulatory characterization “intrinsic factors”, similar concept of stem cell niche support could also hold for them[[13](#_ENREF_13)]. The majority of studies using the isolated CSCs, shows the dominant effect of intrinsic factors on CSC regulation. While, other studies propose a role for the CSC niche[[12](#_ENREF_12)]. This model suggests that less malignant tumors may have more demand on the stem cell-niche but upon cancer progress this dynamic interplay might be weaken or even diminished[[14](#_ENREF_14)].

An inductor of the stem cell phenotype is hypoxia[[15-17](#_ENREF_15)]. The self-protection mechanisms are due to the expression of numerous proteins, which reduce the effects of genotoxic xenobiotics. These include the members of efflux pumps, such as ABCB1-MDR1, ABCC1-MRP1 and ABCG2-BCRP, other specific detoxification systems, such as aldehyde dehydrogenase and increased DNA repair capacity. The symmetric cell division and asymmetric distribution of the DNA can also be regarded as part of stem cell self-protection mechanisms[[9](#_ENREF_9)]. For the tumor stem cells, the existence of the same mechanisms is a crucial cause of their therapeutic resistance.

In addition to hypoxia as a triggering factor, growth factors play an important role, leading to epithelial-mesenchymal transition (EMT) in cells. It is shown a high-level regulation of stem cell markers after the induction of EMT in normal epithelial cells of the breast gland tissue and in mammary carcinoma cells[[18](#_ENREF_18)]. One of the EMT effects can be the induction of the stem cell phenotype[[18](#_ENREF_18)].

Numerous findings could show that routine tumor therapy approaches (classical chemotherapy or radiation therapy) and even the majority of currently used targeted antitumor drugs, so-called biological therapy, have little effect on the tumor stem cells even in chemo- or radio-sensitive tumors[[19](#_ENREF_19)]. While, the stationary tumor stem cells largely retain their epithelial character and are therefore responsible for the primary tumor growth or recurrence, the migrating tumor stem cells exhibit ability for invasion and distance metastasis. This highlights the above-mentioned plasticity of the tumor stem cells (Figure 1).

**THERAPY RESISTANCE IN CSCs**

A small number of immortal cells within the bulk tumor with a character of CSC causes the chemo/radiotherapy resistance. Such cells with stem cell characteristics, seem to grow aggressively and metastasize easily. It is not yet clear how CSCs are formed, whether they develop from tissue stem cells or are formed from differentiated cells by recovering embryonic properties. Chemotherapeutic agents and radiotherapy mainly destroy dividing cells[[20](#_ENREF_20)]. Since CSCs are particularly dormant, in one hand they are not detected by the routine screening measures, and in the other hand, they are positively selected upon the routine therapy approaches.

**MOLECULAR MECHANISMS OF THE THERAPY RESISTANCE OF CSCs**

Central regulators of the cellular response to DNA damage are checkpoint kinases 1 and 2 (Chk1/2), which are activated after genotoxic stress and stop cell proliferation to allow DNA repair. Activation of Chk1 as a response to DNA damage by ionizing radiation or chemotherapy agents can be detected preferentially in CD133+ glioblastoma precursor cells[[21](#_ENREF_21)]. By pharmacological inhibition of Chk1, it was possible to increase the sensitivity of CD133+ glioblastoma precursor cells against therapy[[21](#_ENREF_21)].

An efficient inactivation of reactive oxygen species (ROS) is another feature of CSCs. The excessive production of ROS under chemo/radiotherapy leads to a cell damage because of its interaction with DNA and proteins and triggering the cell death. In some tumors, including mammary carcinoma and gastrointestinal carcinoma, fewer amounts of ROS were detected in CSCs with a simultaneously increased amount of free-radical scavenger compared to the cell populations without CSC phenotype[[22](#_ENREF_22)]. In addition, the expression of stem cell marker CD44 in tumor cells was associated with an increased expression of the glutathione as a free-radical scavenger[[23](#_ENREF_23),[24](#_ENREF_24)]. Pharmacologically induced reduction in the concentration of free-radical scavenger in tumor cells can significantly increase their sensitivity to the chemo/radiotherapy[[25](#_ENREF_25)]. It remains unclear whether the increased CD44 expression as a biomarker is suitable for the detection of ROS-resistant CSCs and thus can identify patients who can benefit from therapy with inhibitors of free-radical scavengers in combination with the chemo/radiotherapy.

Another factor contributing to the chemo/radiotherapy resistance of CSCs is hypoxia. Among other factors, hypoxia is the most common cause of therapy-resistance CSCs, which activates the HIF (hypoxia inducible factor) signaling pathway and triggers cellular processes that can lead to a better survival and expansion of CSCs[[26](#_ENREF_26)]. The presence of hypoxia in the tumor tissue or its decrease by reoxygenation in the course of chemo/radiotherapy could be correlated with an accelerated repopulation of CSCs with therapy-resistance phenotype[[27](#_ENREF_27)].

There are several critical proliferation-promoting and survival-inducing pathways triggering the maintenance and survival of CSCs. The canonical Wnt pathway, which is central signaling pathway for stem cell maintenance and development, is constitutively active in breast cancer, colorectal cancer, myeloid leukemia, lung cancer and skin cancer[[28](#_ENREF_28),[29](#_ENREF_29)]. Hedgehog Signaling (HH), which has three different homologues (Desert Hedgehog (dHH), Indian Hedgehog (iHH) and Sonic Hedgehog (sHH) is essential in a variety of molecular and cellular processes during tissue homeostasis, development or embryogenesis. Aberrant HH activation which regulates the CSC’s maintenance and potential proliferation, is reported in different cancers including acute myeloid leukemia (AML), breast cancer, chronic myeloid leukemia (CML), glioblastoma, lung carcinoma, myeloma, pancreatic adenocarcinoma[[7](#_ENREF_7),[30](#_ENREF_30),[31](#_ENREF_31)]. Canonical Notch signaling is the other conserved signaling pathway in tissue homeostasis and development. Activation of Notch signaling upon binding of the extracellular ligands, regulates the expression of target genes involving in CSC self-renewal such as Myc, Nanog, Oct-4, and Sox2[[32](#_ENREF_32)]. Abnormal Notch activation plays a critical role in breast cancer, myeloid leukemia (AML and CML), glioblastoma, lung cancer and pancreatic cancer[[7](#_ENREF_7),[32](#_ENREF_32),[33](#_ENREF_33)]. Phosphoinositide-3-kinase/protein kinase B (AKT), canonical and non-canonical nuclear factor-ĸB (NF-ĸB), stromal-derived factor-1α/CXCR4, ErbB signaling and hedgehog/glioma-associated oncogene are other critical pathways that regulates CSC-related maintenance and proliferation[[34-38](#_ENREF_34)]. The majority of cancer and CSC-related pathways do not act as isolated units but rather often interact with other pathways as a linked biological network. The predicted crosstalk among Wnt signaling, Notch pathway, Hedgehog signaling and other pathways like EGF/VEGF signaling is illustrated in the Figure 2.

Therefore, therapies that target CSCs could be more effective than therapies targeting a general reduction in tumor mass. Thus, it can be postulated that the efficacy of the chemo/radiotherapy to eradicate CSCs, can be enhanced by a combination therapy with drugs specifically targeting CSCs (Figure 1).

**METHODS FOR SCREENING OF CSCs**

Over the past decade, different CSC markers were identified in a wide range of hematopoietic malignancies and solid tumors[[39](#_ENREF_39),[40](#_ENREF_40)]. A widely used method for characterizing CSC-related markers is multiparameter flow cytometry. This method, which is originally developed for the analysis of blood cells and hematopoietic stem cells, offers the possibility to detect CSCs by means of specific surface markers that are stained with fluorescence-coupled antibodies. Frequently, the expression of CD133 or CD44 alone or in combination with further markers such as CD20, CD24, CD90 or α2-β1-integrin is used as a CSC-specific marker (Figure 3). Functional detection of CSC is also possible and is based on the increased expression of detoxification enzyme aldehyde dehydrogenase 1 (*ALDH1*) or the high activity of multidrug resistance transport proteins. These CSC-specific staining methods allow the isolation of single CSCs for further molecular characterization using single cell based molecular approaches (Figure 3). However, identified markers are not always reliable and none of the reported markers solely identify CSCs, therefore need to be used with caution (Table 1).

For example, inter- or intra-tumor heterogeneity may completely render CSC markers inapt. Such tumor heterogeneity can be the result of different genetically distinct clones within the tumor due to having various genetic lesions or dysregulation of markers *via* pathologic epigenetic regulations[[16](#_ENREF_16),[37-43](#_ENREF_37)]. For example, CD133 marker is frequently inactivated due to the DNA methylation and therefore often inadequate[[44](#_ENREF_44)]. Inactivation of specific markers due to any scape mechanism in a particular clone may render these CSCs undetectable in the absence of other distinct markers.

While high-throughput genetic screening studies provide essential information about genes which are associated with a particular phenotype, molecular pharmacology can play an important role in development of a specific molecular therapy. Low molecular weight substances (“small molecules”) show a higher penetrance in cell-based screening methods. Therefore, small molecules are one of the most frequently used therapeutic agents. The screening of large substance banks has identified many valuable compounds that can be used to modulate biological systems in cancer cells[[45](#_ENREF_45)]. In order to systematically identify the genes that regulate the death and differentiation of CSCs, high-throughput screenings of RNA interference (RNAi) or chemical substance libraries are carried out using different approaches. The readout of such screen approaches can be survival analysis, reporter assays, luminescence or fluorescence-based analyzes of particular genes or pathways and imaging methods, in which several cellular properties can be examined on a single cell level.

Since CSCs only make up a small fraction in the entire tumor cell pool (Figure 1), appropriate enrichment methods must be applied. Gupta *et al*[[46](#_ENREF_46)] enriched CD44hi/CD24lo cells within the CSC population of mammary carcinoma cell lines by inducing the EMT. After treatment with inhibitors, the survival of the enriched and the non-selected cell population was investigated using a luminescence-based reporter assay. This study was able to identify salinomycin as a selective inhibitor of the CSC population in breast carcinoma[[46](#_ENREF_46)].

Recent advances in computer-based image analysis have enabled rapid achievements in the development of image-based high-throughput analysis approaches. The direct visualization of cellular features and biological processes allows a more comprehensive measurement of responses to interferences. Xia *et al*[[47](#_ENREF_47)] have developed a novel fluorescence imaging method to identify cancer cells with CSC properties through their increased ability to deliver fluorescent dyes *via* dedicated molecular transporters. Based on this method, a library of active substances was examined for their effect in CSCs. It was possible to identify substances that selectively inhibit the molecular transporters[[47](#_ENREF_47)].

A further high-throughput method has recently been developed to characterize the biochemical and biophysical environmental conditions of CSCs. Microarray glass slides with over 2000 test chambers can be used to cultivate stem cells in different cell densities in a hydrogel of polyethylene glycol, to which different biological molecules have been coupled by robot technology[[48](#_ENREF_48)]. Using the microscopic imaging, cell proliferation, morphology and differentiation can be monitored at a single cell level. This method as a platform for the investigation of individual stem cells in a microfluid culture system with simultaneous live-cell microscopy, represents an important step towards the miniaturization of the cellular processes as a high-throughput screening approach[[49](#_ENREF_49)].

**TARGETING CSCs**

***Targeting tumor microenvironment***

The heterogeneous tumor microenvironment or cancer cell-niche, provides different self-protection mechanisms which enables a dynamic interaction with surrounding cells including immune cells, cytokines and chemokines to regulate proliferation, maintenance and self-renewal of CSCs. CSCs can represent more autonomous regulatory characterization in an independent manner[[13](#_ENREF_13)]. Less malignant tumors may have more demand on the stem cell-niche but upon cancer progress this dynamic interplay might be weaken or even diminished[[14](#_ENREF_14)]. It is known that dormant cancer cells *via* reducing their immunogenicity, can escape the immune surveillance[[50](#_ENREF_50)]. Therefore, targeting CSC microenvironment may stimulate the host antitumor responses[[51](#_ENREF_51)]. Strategies to hit the tumor-promoting inflammation are under investigation. Production of prostaglandin E2 (PGE2) by tumor cells in breast cancer, colorectal cancer and melanoma has a key role in the escape phase as it suppresses immunity and induces inflammation[[52](#_ENREF_52)]. Therefore, the use of antagonists of PGE2 receptor (PTGER4) has proven successful in blocking immuno-suppression and preventing cancer metastases[[53](#_ENREF_53)].

***Targeting efflux transporters***

Membrane efflux transporters, which are mainly located in blood-brain barrier, hepatocytes, intestinal cells or kidney proximal tubules, play important roles in drug metabolism, availability, and toxicity of drugs in human body[[54](#_ENREF_54)]. Several studies indicate that transporter-mediated drug disposition plays an important role in mediating chemo-sensitivity and -resistance of cancer cells and CSCs[[55](#_ENREF_55)]. The interaction between efflux transporters and chemotherapeutic drugs on cancer cells is significantly linked to the efficacy of cancer therapy. Two major superfamilies of efflux transporters are the ATP-binding cassette (ABC) transporters [ABCB1 (MDR1), ABCC1 (MRP1), ABCC2 (MRP2) and ABCG2 (BCRP)] and the solute carrier (SLC) transporters [SLC19A1 (RFC1) and SLCO1B1 (SLC21A6)]. Therefore, targeting efflux transporters within cancer therapy combined with routine therapies could significantly increase the eradication rate of resistant cancer cells[[56](#_ENREF_56)].

***Targeting key signaling pathways***

The CSC phenotype depends on various cellular signals, which are triggered by the underlying genetic lesions and by the support of the stem cell niche. Some of these signals have already been identified; the most disease cussed signaling pathways are the classic Wnt-β-catenin, Notch and Sonic Hedgehog signaling[[57-59](#_ENREF_57)]. For these three pathways, pharmacological inhibitors have been developed which are now undergoing clinical trials in many independent studies[[60](#_ENREF_60)]. However, the clinical effect is largely depending on the tumor type and not all three pathways are equally important in all types of tumors. It has been shown that, although some signaling pathways are highly tumor-promoting in a certain type of cancers (which makes it a suitable therapeutic target), they might react as tumor suppressive in another tumor type; therefore, their inhibition may become dangerous (*e.g.*, Notch-1 has been identified as a tumor suppressor in urinary bladder carcinoma)[[61](#_ENREF_61)]. High Wnt pathway activity marks colon or leukemia CSCs and is required for stemness signature as a prognostic marker[[6](#_ENREF_6),[7](#_ENREF_7),[62](#_ENREF_62)]. In addition, Wnt activity is associated with the CSC markers CD133, CD44 and LGR5 in colon cancer[[63](#_ENREF_63)] whereas Hedgehog activity is linked to ABC transporter expression in esophageal and prostate cancer[[17](#_ENREF_17),[64](#_ENREF_64)] TGF-β signaling *via* the family members Nodal and Activin is attributed to pancreatic CSCs[[65](#_ENREF_65)]. The effect of Hedgehog inhibitors is actually the most evident in the basal cell carcinoma. In addition, inhibition of Hedgehog pathway blocks stemness in breast CSCs, whereas its activation enhances self-renewal[[66](#_ENREF_66)]. It is also necessary to distinguish whether those signaling pathway has been activated within CSCs only because of harbored genetic lesions[[67](#_ENREF_67)]. If only the CSCs are targeted, it is hardly possible to expect a dramatic tumor shrinkage as in classical successful chemo/radiotherapy; rather, this would be a disease stabilization and a slowing of the progression (Figure 1).

Disulfiram was developed as an inhibitor of aldehyde dehydrogenase for the treatment of alcoholism. This inhibition leads to the accumulation of acetaldehyde after alcohol consumption, resulting in a marked nausea that should reduce the probability of further alcohol consumption[[68](#_ENREF_68)]. The same enzymatic activity - aldehyde dehydrogenase - is, however, a component of the self-protection of the CSCs, and thus disulfiram was used for the elimination of CSCs. Thioridazine is an inhibitor of dopamine receptors, and is a standard medication for mental disorders such as schizophrenia. Its rational use in tumor therapy is based on the finding that CSCs in several types of tumors (*e.g*., AML, breast carcinoma, glioblastoma), in contrast to the corresponding normal tissue stem cells, upregulate the expression of dopamine receptors[[69](#_ENREF_69)].

Niclosamide was identified that specifically targeted Wnt-β-catenin signaling pathways[[70](#_ENREF_70)]. Interestingly, niclosamide is known as an antiparasitic and inhibitor of oxidative phosphorylation, which has been used in human medicine for almost 50 years[[71](#_ENREF_71)]. However, what has emerged is that these two antiparasitics are inhibitors of numerous other signaling pathways. Niclosamide inhibits not only the Wnt-β-catenin signaling pathway, but also the Notch, PI3’K-Akt - mTOR, STAT-3 and NFκB signaling pathways, which are essential for tumor stem cells[[72](#_ENREF_72)]. Salinomycin was similarly described as an inhibitor of ABC efflux pumps and the Wnt-β-catenin signaling pathway[[73](#_ENREF_73)]. Not enough, analogous effects have been discovered for disulfiram and thioridazine. Disulfiram has not only proved to be an effective inhibitor of aldehyde dehydrogenase, but also polo-like kinase 1 and O6-methylguanine methyltransferase as well as NFκB[[74](#_ENREF_74),[75](#_ENREF_75)].

The advantages of identifying such new indications for old drugs are obvious. These drugs have long been out of patent protection and their use should therefore be much cheaper than for newly developed drugs, which is an important aspect in the current discussion on costs of tumor treatment. In addition, they have already undergone clinical trials, their potential toxicity, side effects, pharmacokinetics, contraindications, and possible drug-drug interactions are known. Therefore, their use in tumor therapy should be relatively easy. Perhaps the best opportunity to see how the effects of tumor stem cell-targeted therapy can be demonstrated is in the area of ​​combination therapy (Figure 1). Tumor stem cell-directed drugs should be able to prolong the efficacy of cytotoxic therapy and reduce recurrence risk[[76](#_ENREF_76),[77](#_ENREF_77)]. On the other hand, combined administration has significantly greater chances of total elimination of all tumor cells. Taken together, there are many possibilities for therapeutic treatment for the elimination of tumor stem cells, both from the group of newly developed inhibitors of some stem cell-specific signaling pathways as well as for some old drugs that can find a new application in tumor therapy.

***Targeting cellular surface markers (tumor immunotherapy and cancer vaccination)***

Many types of normal cells like immune cells infiltrate tumors. Over the last years, immune infiltration has become a central focus in cancer research[[50](#_ENREF_50)]. It is increasingly recognized that cancer cells and CSCs need to escape immune recognition. IL-6/JAK/STAT3 signaling an important pathway in many solid tumors. Anti-IL-6 mAb siltux-imab was tested on various cancer types, which was not able to provide promising outcome to improve overall survival of patients with multiple myeloma according to a recent Phase II clinical trial on patients[[78](#_ENREF_78)]. While, checkpoint blockade antibodies such as cytotoxic T-lymphocyte antigen 4 (CTLA-4) or programmed death-ligand 1 (PD-1/PD-L1) like ipilimumab or nivolumab could provide marked clinical benefits for lung adenocarcinoma, melanoma or Hodgkin lymphomas[[79](#_ENREF_79),[80](#_ENREF_80)]. These agents can boost the immune system and display clinical benefits for a fraction of patients[[50](#_ENREF_50)].

Many tumors cells including CSCs, alter the expression of their genes or down-modulate of antigen processing and presentation to build an immuno-suppressive microenvironment that creates physical or chemical barriers against immune cells[[81](#_ENREF_81)]. Indeed, CSCs by low express of MHC-I, and over expressing of IL-4 are escaping from cytotoxic T lymphocytes[[82](#_ENREF_82)]. Boosting T-cell response can be a promising approach to eradicate CSCs. This can be achieved by boosting neo-antigens within CSCs, considered as tumor vaccination. Adoptive transfer of CSC-specific T-cells into tumor-bearing mice could show a success[[83](#_ENREF_83)]. In addition, genetically modified T cells to express chimeric antigen receptors (CAR T-cells) upon adaptive transfer could provide remarkable benefit for patients suffering from different solid tumors or leukemia[[84](#_ENREF_84)]. Therefore, the major goal of immunotherapy is to thwart these barriers in order to enhance pre-existing or elicit a new immune response against cancer.

**CONCLUSION**Because of the CSCs’ ability to therapy-resistance and initiate a recurrence after therapy, cancer stem cell is an important therapeutic target. Future research is essential to elucidate how CSCs dictate metastasis, therapy-resistance or immune-scape signature. However, without having reliable markers it will be a challenging pursuit. An exact molecular characterization of this small subpopulation in the tumor tissue requires the development of specific CSC markers and suitable enrichment methods. Particularly from innovative high-throughput screening technologies, we can expect valuable insights regarding suitable CSC-associated biomarkers and new therapeutic approaches to target CSCs. This could be an important step towards individualized cancer therapy.

**REFERENCES**

1 **Dontu G**, Abdallah WM, Foley JM, Jackson KW, Clarke MF, Kawamura MJ, Wicha MS. In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. *Genes Dev* 2003; **17**: 1253-1270 [PMID: 12756227 DOI: 10.1101/gad.1061803]

2 **Hatina J**. The dynamics of cancer stem cells. *Neoplasma* 2012; **59**: 700-707 [PMID: 22862171 DOI: 10.4149/neo\_2012\_092]

3 **Vermeulen L**, de Sousa e Melo F, Richel DJ, Medema JP. The developing cancer stem-cell model: clinical challenges and opportunities. *Lancet Oncol* 2012; **13**: e83-e89 [PMID: 22300863 DOI: 10.1016/s1470-2045(11)70257-1]

4 **Lapidot T**, Sirard C, Vormoor J, Murdoch B, Hoang T, Caceres-Cortes J, Minden M, Paterson B, Caligiuri MA, Dick JE. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. *Nature* 1994; **367**: 645-648 [PMID: 7509044 DOI: 10.1038/367645a0]

5 **Visvader JE**, Lindeman GJ. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. *Nat Rev Cancer* 2008; **8**: 755-768 [PMID: 18784658 DOI: 10.1038/nrc2499]

6 **Riether C**, Schürch CM, Flury C, Hinterbrandner M, Drück L, Huguenin AL, Baerlocher GM, Radpour R, Ochsenbein AF. Tyrosine kinase inhibitor-induced CD70 expression mediates drug resistance in leukemia stem cells by activating Wnt signaling. *Sci Transl Med* 2015; **7**: 298ra119 [PMID: 26223302 DOI: 10.1126/scitranslmed.aab1740]

7 **Riether C**, Schürch CM, Bührer ED, Hinterbrandner M, Huguenin AL, Hoepner S, Zlobec I, Pabst T, Radpour R, Ochsenbein AF. CD70/CD27 signaling promotes blast stemness and is a viable therapeutic target in acute myeloid leukemia. *J Exp Med* 2017; **214**: 359-380 [PMID: 28031480 DOI: 10.1084/jem.20152008]

8 **Baumann M**, Krause M, Hill R. Exploring the role of cancer stem cells in radioresistance. *Nat Rev Cancer* 2008; **8**: 545-554 [PMID: 18511937 DOI: 10.1038/nrc2419]

9 **Meacham CE**, Morrison SJ. Tumour heterogeneity and cancer cell plasticity. *Nature* 2013; **501**: 328-337 [PMID: 24048065 DOI: 10.1038/nature12624]

10 **Plaks V**, Kong N, Werb Z. The cancer stem cell niche: how essential is the niche in regulating stemness of tumor cells? *Cell Stem Cell* 2015; **16**: 225-238 [PMID: 25748930 DOI: 10.1016/j.stem.2015.02.015]

11 **Medema JP**, Vermeulen L. Microenvironmental regulation of stem cells in intestinal homeostasis and cancer. *Nature* 2011; **474**: 318-326 [PMID: 21677748 DOI: 10.1038/nature10212]

12 **Shestopalov IA**, Zon LI. Stem cells: The right neighbour. *Nature* 2012; **481**: 453-455 [PMID: 22281591 DOI: 10.1038/481453a]

13 **Borovski T**, De Sousa E Melo F, Vermeulen L, Medema JP. Cancer stem cell niche: the place to be. *Cancer Res* 2011; **71**: 634-639 [PMID: 21266356 DOI: 10.1158/0008-5472.can-10-3220]

14 **Quintana E**, Shackleton M, Sabel MS, Fullen DR, Johnson TM, Morrison SJ. Efficient tumour formation by single human melanoma cells. *Nature* 2008; **456**: 593-598 [PMID: 19052619 DOI: 10.1038/nature07567]

15 **Mohyeldin A**, Garzón-Muvdi T, Quiñones-Hinojosa A. Oxygen in stem cell biology: a critical component of the stem cell niche. *Cell Stem Cell* 2010; **7**: 150-161 [PMID: 20682444 DOI: 10.1016/j.stem.2010.07.007]

16 **Barekati Z**, Radpour R, Kohler C, Zhang B, Toniolo P, Lenner P, Lv Q, Zheng H, Zhong XY. Methylation profile of TP53 regulatory pathway and mtDNA alterations in breast cancer patients lacking TP53 mutations. *Hum Mol Genet* 2010; **19**: 2936-2946 [PMID: 20466735 DOI: 10.1093/hmg/ddq199]

17 **Medema JP**. Cancer stem cells: the challenges ahead. *Nat Cell Biol* 2013; **15**: 338-344 [PMID: 23548926 DOI: 10.1038/ncb2717]

18 **Mani SA**, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, Campbell LL, Polyak K, Brisken C, Yang J, Weinberg RA. The epithelial-mesenchymal transition generates cells with properties of stem cells. *Cell* 2008; **133**: 704-715 [PMID: 18485877 DOI: 10.1016/j.cell.2008.03.027]

19 **Abdullah LN**, Chow EK. Mechanisms of chemoresistance in cancer stem cells. *Clin Transl Med* 2013; **2**: 3 [PMID: 23369605 DOI: 10.1186/2001-1326-2-3]

20 **Wicha MS**, Hayes DF. Circulating tumor cells: not all detected cells are bad and not all bad cells are detected. *J Clin Oncol* 2011; **29**: 1508-1511 [PMID: 21422428 DOI: 10.1200/jco.2010.34.0026]

21 **Bao S**, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, Dewhirst MW, Bigner DD, Rich JN. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. *Nature* 2006; **444**: 756-760 [PMID: 17051156 DOI: 10.1038/nature05236]

22 **Diehn M**, Cho RW, Lobo NA, Kalisky T, Dorie MJ, Kulp AN, Qian D, Lam JS, Ailles LE, Wong M, Joshua B, Kaplan MJ, Wapnir I, Dirbas FM, Somlo G, Garberoglio C, Paz B, Shen J, Lau SK, Quake SR, Brown JM, Weissman IL, Clarke MF. Association of reactive oxygen species levels and radioresistance in cancer stem cells. *Nature* 2009; **458**: 780-783 [PMID: 19194462 DOI: 10.1038/nature07733]

23 **Baumann M**, Krause M. CD44: a cancer stem cell-related biomarker with predictive potential for radiotherapy. *Clin Cancer Res* 2010; **16**: 5091-5093 [PMID: 20861165 DOI: 10.1158/1078-0432.CCR-10-2244]

24 **Kokko LL**, Hurme S, Maula SM, Alanen K, Grénman R, Kinnunen I, Ventelä S. Significance of site-specific prognosis of cancer stem cell marker CD44 in head and neck squamous-cell carcinoma. *Oral Oncol* 2011; **47**: 510-516 [PMID: 21514878 DOI: 10.1016/j.oraloncology.2011.03.026]

25 **Ishimoto T**, Nagano O, Yae T, Tamada M, Motohara T, Oshima H, Oshima M, Ikeda T, Asaba R, Yagi H, Masuko T, Shimizu T, Ishikawa T, Kai K, Takahashi E, Imamura Y, Baba Y, Ohmura M, Suematsu M, Baba H, Saya H. CD44 variant regulates redox status in cancer cells by stabilizing the xCT subunit of system xc(-) and thereby promotes tumor growth. *Cancer Cell* 2011; **19**: 387-400 [PMID: 21397861 DOI: 10.1016/j.ccr.2011.01.038]

26 **Morrison R**, Schleicher SM, Sun Y, Niermann KJ, Kim S, Spratt DE, Chung CH, Lu B. Targeting the mechanisms of resistance to chemotherapy and radiotherapy with the cancer stem cell hypothesis. *J Oncol* 2011; **2011**: 941876 [PMID: 20981352 DOI: 10.1155/2011/941876]

27 **Kim JJ**, Tannock IF. Repopulation of cancer cells during therapy: an important cause of treatment failure. *Nat Rev Cancer* 2005; **5**: 516-525 [PMID: 15965493 DOI: 10.1038/nrc1650]

28 **Heidel FH**, Bullinger L, Feng Z, Wang Z, Neff TA, Stein L, Kalaitzidis D, Lane SW, Armstrong SA. Genetic and pharmacologic inhibition of β-catenin targets imatinib-resistant leukemia stem cells in CML. *Cell Stem Cell* 2012; **10**: 412-424 [PMID: 22482506 DOI: 10.1016/j.stem.2012.02.017]

29 **Malanchi I**, Peinado H, Kassen D, Hussenet T, Metzger D, Chambon P, Huber M, Hohl D, Cano A, Birchmeier W, Huelsken J. Cutaneous cancer stem cell maintenance is dependent on beta-catenin signalling. *Nature* 2008; **452**: 650-653 [PMID: 18385740 DOI: 10.1038/nature06835]

30 **Merchant AA**, Matsui W. Targeting Hedgehog--a cancer stem cell pathway. *Clin Cancer Res* 2010; **16**: 3130-3140 [PMID: 20530699 DOI: 10.1158/1078-0432.ccr-09-2846]

31 **Dierks C**, Beigi R, Guo GR, Zirlik K, Stegert MR, Manley P, Trussell C, Schmitt-Graeff A, Landwerlin K, Veelken H, Warmuth M. Expansion of Bcr-Abl-positive leukemic stem cells is dependent on Hedgehog pathway activation. *Cancer Cell* 2008; **14**: 238-249 [PMID: 18772113 DOI: 10.1016/j.ccr.2008.08.003]

32 **Miele L**. Notch signaling. *Clin Cancer Res* 2006; **12**: 1074-1079 [PMID: 16489059 DOI: 10.1158/1078-0432.ccr-05-2570]

33 **Chen Y**, Li D, Liu H, Xu H, Zheng H, Qian F, Li W, Zhao C, Wang Z, Wang X. Notch-1 signaling facilitates survivin expression in human non-small cell lung cancer cells. *Cancer Biol Ther* 2011; **11**: 14-21 [PMID: 20962575]

34 **Hambardzumyan D**, Becher OJ, Holland EC. Cancer stem cells and survival pathways. *Cell Cycle* 2008; **7**: 1371-1378 [PMID: 18421251 DOI: 10.4161/cc.7.10.5954]

35 **Dubrovska A**, Kim S, Salamone RJ, Walker JR, Maira SM, García-Echeverría C, Schultz PG, Reddy VA. The role of PTEN/Akt/PI3K signaling in the maintenance and viability of prostate cancer stem-like cell populations. *Proc Natl Acad Sci USA* 2009; **106**: 268-273 [PMID: 19116269 DOI: 10.1073/pnas.0810956106]

36 **Dubrovska A**, Elliott J, Salamone RJ, Telegeev GD, Stakhovsky AE, Schepotin IB, Yan F, Wang Y, Bouchez LC, Kularatne SA, Watson J, Trussell C, Reddy VA, Cho CY, Schultz PG. CXCR4 expression in prostate cancer progenitor cells. *PLoS One* 2012; **7**: e31226 [PMID: 22359577 DOI: 10.1371/journal.pone.0031226]

37 **Radpour R**, Barekati Z, Kohler C, Lv Q, Bürki N, Diesch C, Bitzer J, Zheng H, Schmid S, Zhong XY. Hypermethylation of tumor suppressor genes involved in critical regulatory pathways for developing a blood-based test in breast cancer. *PLoS One* 2011; **6**: e16080 [PMID: 21283676 DOI: 10.1371/journal.pone.0016080]

38 **Radpour R**, Kohler C, Haghighi MM, Fan AX, Holzgreve W, Zhong XY. Methylation profiles of 22 candidate genes in breast cancer using high-throughput MALDI-TOF mass array. *Oncogene* 2009; **28**: 2969-2978 [PMID: 19503099 DOI: 10.1038/onc.2009.149]

39 **Radpour R**, Barekati Z, Kohler C, Holzgreve W, Zhong XY. New trends in molecular biomarker discovery for breast cancer. *Genet Test Mol Biomarkers* 2009; **13**: 565-571 [PMID: 19814613 DOI: 10.1089/gtmb.2009.0060]

40 **Aghagolzadeh P**, Radpour R. New trends in molecular and cellular biomarker discovery for colorectal cancer. *World J Gastroenterol* 2016; **22**: 5678-5693 [PMID: 27433083 DOI: 10.3748/wjg.v22.i25.5678]

41 **Radpour R**, Haghighi MM, Fan AX, Torbati PM, Hahn S, Holzgreve W, Zhong XY. High-throughput hacking of the methylation patterns in breast cancer by in vitro transcription and thymidine-specific cleavage mass array on MALDI-TOF silico-chip. *Mol Cancer Res* 2008; **6**: 1702-1709 [PMID: 19010818 DOI: 10.1158/1541-7786.MCR-08-0262]

42 **Radpour R**, Barekati Z, Kohler C, Schumacher MM, Grussenmeyer T, Jenoe P, Hartmann N, Moes S, Letzkus M, Bitzer J, Lefkovits I, Staedtler F, Zhong XY. Integrated epigenetics of human breast cancer: synoptic investigation of targeted genes, microRNAs and proteins upon demethylation treatment. *PLoS One* 2011; **6**: e27355 [PMID: 22076154 DOI: 10.1371/journal.pone.0027355]

43 **Barekati Z**, Radpour R, Lu Q, Bitzer J, Zheng H, Toniolo P, Lenner P, Zhong XY. Methylation signature of lymph node metastases in breast cancer patients. *BMC Cancer* 2012; **12**: 244 [PMID: 22695536 DOI: 10.1186/1471-2407-12-244]

44 **Yi JM**, Tsai HC, Glöckner SC, Lin S, Ohm JE, Easwaran H, James CD, Costello JF, Riggins G, Eberhart CG, Laterra J, Vescovi AL, Ahuja N, Herman JG, Schuebel KE, Baylin SB. Abnormal DNA methylation of CD133 in colorectal and glioblastoma tumors. *Cancer Res* 2008; **68**: 8094-8103 [PMID: 18829568 DOI: 10.1158/0008-5472.can-07-6208]

45 **Winquist RJ**, Furey BF, Boucher DM. Cancer stem cells as the relevant biomass for drug discovery. *Curr Opin Pharmacol* 2010; **10**: 385-390 [PMID: 20630801 DOI: 10.1016/j.coph.2010.06.008]

46 **Gupta PB**, Onder TT, Jiang G, Tao K, Kuperwasser C, Weinberg RA, Lander ES. Identification of selective inhibitors of cancer stem cells by high-throughput screening. *Cell* 2009; **138**: 645-659 [PMID: 19682730 DOI: 10.1016/j.cell.2009.06.034]

47 **Xia X**, Yang J, Li F, Li Y, Zhou X, Dai Y, Wong ST. Image-based chemical screening identifies drug efflux inhibitors in lung cancer cells. *Cancer Res* 2010; **70**: 7723-7733 [PMID: 20841476 DOI: 10.1158/0008-5472.CAN-09-4360]

48 **Gobaa S**, Hoehnel S, Roccio M, Negro A, Kobel S, Lutolf MP. Artificial niche microarrays for probing single stem cell fate in high throughput. *Nat Methods* 2011; **8**: 949-955 [PMID: 21983923 DOI: 10.1038/nmeth.1732]

49 **Lecault V**, Vaninsberghe M, Sekulovic S, Knapp DJ, Wohrer S, Bowden W, Viel F, McLaughlin T, Jarandehei A, Miller M, Falconnet D, White AK, Kent DG, Copley MR, Taghipour F, Eaves CJ, Humphries RK, Piret JM, Hansen CL. High-throughput analysis of single hematopoietic stem cell proliferation in microfluidic cell culture arrays. *Nat Methods* 2011; **8**: 581-586 [PMID: 21602799 DOI: 10.1038/nmeth.1614]

50 **Fridman WH**, Pagès F, Sautès-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. *Nat Rev Cancer* 2012; **12**: 298-306 [PMID: 22419253 DOI: 10.1038/nrc3245]

51 **Pitt JM**, Marabelle A, Eggermont A, Soria JC, Kroemer G, Zitvogel L. Targeting the tumor microenvironment: removing obstruction to anticancer immune responses and immunotherapy. *Ann Oncol* 2016; **27**: 1482-1492 [PMID: 27069014 DOI: 10.1093/annonc/mdw168]

52 **Zelenay S**, van der Veen AG, Böttcher JP, Snelgrove KJ, Rogers N, Acton SE, Chakravarty P, Girotti MR, Marais R, Quezada SA, Sahai E, Reis e Sousa C. Cyclooxygenase-Dependent Tumor Growth through Evasion of Immunity. *Cell* 2015; **162**: 1257-1270 [PMID: 26343581 DOI: 10.1016/j.cell.2015.08.015]

53 **Ma X**, Holt D, Kundu N, Reader J, Goloubeva O, Take Y, Fulton AM. A prostaglandin E (PGE) receptor EP4 antagonist protects natural killer cells from PGE<sub>2</sub>-mediated immunosuppression and inhibits breast cancer metastasis. *Oncoimmunology* 2013; **2**: e22647 [PMID: 23482441 DOI: 10.4161/onci.22647]

54 **Bodó A**, Bakos E, Szeri F, Váradi A, Sarkadi B. The role of multidrug transporters in drug availability, metabolism and toxicity. *Toxicol Lett* 2003; **140-141**: 133-143 [PMID: 12676459]

55 **Huang Y**, Sadée W. Membrane transporters and channels in chemoresistance and -sensitivity of tumor cells. *Cancer Lett* 2006; **239**: 168-182 [PMID: 16169662 DOI: 10.1016/j.canlet.2005.07.032]

56 **Huang Y**. Pharmacogenetics/genomics of membrane transporters in cancer chemotherapy. *Cancer Metastasis Rev* 2007; **26**: 183-201 [PMID: 17323126 DOI: 10.1007/s10555-007-9050-6]

57 **Hoesel B**, Schmid JA. The complexity of NF-κB signaling in inflammation and cancer. *Mol Cancer* 2013; **12**: 86 [PMID: 23915189 DOI: 10.1186/1476-4598-12-86]

58 **Staal FJ**, Famili F, Garcia Perez L, Pike-Overzet K. Aberrant Wnt Signaling in Leukemia. *Cancers* (Basel) 2016; **8**: pii: E78 [PMID: 27571104 DOI: 10.3390/cancers8090078]

59 **Tohda S**. NOTCH signaling roles in acute myeloid leukemia cell growth and interaction with other stemness-related signals. *Anticancer Res* 2014; **34**: 6259-6264 [PMID: 25368222]

60 **Takebe N**, Miele L, Harris PJ, Jeong W, Bando H, Kahn M, Yang SX, Ivy SP. Targeting Notch, Hedgehog, and Wnt pathways in cancer stem cells: clinical update. *Nat Rev Clin Oncol* 2015; **12**: 445-464 [PMID: 25850553 DOI: 10.1038/nrclinonc.2015.61]

61 **Rampias T**, Vgenopoulou P, Avgeris M, Polyzos A, Stravodimos K, Valavanis C, Scorilas A, Klinakis A. A new tumor suppressor role for the Notch pathway in bladder cancer. *Nat Med* 2014; **20**: 1199-1205 [PMID: 25194568 DOI: 10.1038/nm.3678]

62 **Vermeulen L**, De Sousa E Melo F, van der Heijden M, Cameron K, de Jong JH, Borovski T, Tuynman JB, Todaro M, Merz C, Rodermond H, Sprick MR, Kemper K, Richel DJ, Stassi G, Medema JP. Wnt activity defines colon cancer stem cells and is regulated by the microenvironment. *Nat Cell Biol* 2010; **12**: 468-476 [PMID: 20418870 DOI: 10.1038/ncb2048]

63 **Van der Flier LG**, Sabates-Bellver J, Oving I, Haegebarth A, De Palo M, Anti M, Van Gijn ME, Suijkerbuijk S, Van de Wetering M, Marra G, Clevers H. The Intestinal Wnt/TCF Signature. *Gastroenterology* 2007; **132**: 628-632 [PMID: 17320548 DOI: 10.1053/j.gastro.2006.08.039]

64 **Sims-Mourtada J**, Izzo JG, Ajani J, Chao KS. Sonic Hedgehog promotes multiple drug resistance by regulation of drug transport. *Oncogene* 2007; **26**: 5674-5679 [PMID: 17353904 DOI: 10.1038/sj.onc.1210356]

65 **Lonardo E**, Hermann PC, Mueller MT, Huber S, Balic A, Miranda-Lorenzo I, Zagorac S, Alcala S, Rodriguez-Arabaolaza I, Ramirez JC, Torres-Ruíz R, Garcia E, Hidalgo M, Cebrián DÁ, Heuchel R, Löhr M, Berger F, Bartenstein P, Aicher A, Heeschen C. Nodal/Activin signaling drives self-renewal and tumorigenicity of pancreatic cancer stem cells and provides a target for combined drug therapy. *Cell Stem Cell* 2011; **9**: 433-446 [PMID: 22056140 DOI: 10.1016/j.stem.2011.10.001]

66 **Liu S**, Dontu G, Mantle ID, Patel S, Ahn NS, Jackson KW, Suri P, Wicha MS. Hedgehog signaling and Bmi-1 regulate self-renewal of normal and malignant human mammary stem cells. *Cancer Res* 2006; **66**: 6063-6071 [PMID: 16778178 DOI: 10.1158/0008-5472.can-06-0054]

67 **Amakye D**, Jagani Z, Dorsch M. Unraveling the therapeutic potential of the Hedgehog pathway in cancer. *Nat Med* 2013; **19**: 1410-1422 [PMID: 24202394 DOI: 10.1038/nm.3389]

68 **Mutschler J**, Kiefer F. [Mechanism of action of disulfiram and treatment optimization in prevention of recurrent alcoholism]. *Praxis* (Bern 1994) 2013; **102**: 139-146 [PMID: 23384983 DOI: 10.1024/1661-8157/a001178]

69 **Sachlos E**, Risueño RM, Laronde S, Shapovalova Z, Lee JH, Russell J, Malig M, McNicol JD, Fiebig-Comyn A, Graham M, Levadoux-Martin M, Lee JB, Giacomelli AO, Hassell JA, Fischer-Russell D, Trus MR, Foley R, Leber B, Xenocostas A, Brown ED, Collins TJ, Bhatia M. Identification of drugs including a dopamine receptor antagonist that selectively target cancer stem cells. *Cell* 2012; **149**: 1284-1297 [PMID: 22632761 DOI: 10.1016/j.cell.2012.03.049]

70 **Chen M**, Wang J, Lu J, Bond MC, Ren XR, Lyerly HK, Barak LS, Chen W. The anti-helminthic niclosamide inhibits Wnt/Frizzled1 signaling. *Biochemistry* 2009; **48**: 10267-10274 [PMID: 19772353 DOI: 10.1021/bi9009677]

71 **Al-Hadiya BM**. Niclosamide: comprehensive profile. *Profiles Drug Subst Excip Relat Methodol* 2005; **32**: 67-96 [PMID: 22469082 DOI: 10.1016/S0099-5428(05)32002-8]

72 **Li Y**, Li PK, Roberts MJ, Arend RC, Samant RS, Buchsbaum DJ. Multi-targeted therapy of cancer by niclosamide: A new application for an old drug. *Cancer Lett* 2014; **349**: 8-14 [PMID: 24732808 DOI: 10.1016/j.canlet.2014.04.003]

73 **Boesch M**, Zeimet AG, Rumpold H, Gastl G, Sopper S, Wolf D. Drug Transporter-Mediated Protection of Cancer Stem Cells From Ionophore Antibiotics. *Stem Cells Transl Med* 2015; **4**: 1028-1032 [PMID: 26136502 DOI: 10.5966/sctm.2015-0054]

74 **Triscott J**, Lee C, Hu K, Fotovati A, Berns R, Pambid M, Luk M, Kast RE, Kong E, Toyota E, Yip S, Toyota B, Dunn SE. Disulfiram, a drug widely used to control alcoholism, suppresses the self-renewal of glioblastoma and over-rides resistance to temozolomide. *Oncotarget* 2012; **3**: 1112-1123 [PMID: 23047041 DOI: 10.18632/oncotarget.604]

75 **Wang Y**, Li W, Patel SS, Cong J, Zhang N, Sabbatino F, Liu X, Qi Y, Huang P, Lee H, Taghian A, Li JJ, DeLeo AB, Ferrone S, Epperly MW, Ferrone CR, Ly A, Brachtel EF, Wang X. Blocking the formation of radiation-induced breast cancer stem cells. *Oncotarget* 2014; **5**: 3743-3755 [PMID: 25003837 DOI: 10.18632/oncotarget.1992]

76 **Ke XY**, Lin Ng VW, Gao SJ, Tong YW, Hedrick JL, Yang YY. Co-delivery of thioridazine and doxorubicin using polymeric micelles for targeting both cancer cells and cancer stem cells. *Biomaterials* 2014; **35**: 1096-1108 [PMID: 24183698 DOI: 10.1016/j.biomaterials.2013.10.049]

77 **Murone M**, Radpour R, Attinger A, Chessex AV, Huguenin AL, Schürch CM, Banz Y, Sengupta S, Aguet M, Rigotti S, Bachhav Y, Massière F, Ramachandra M, McAllister A, Riether C. The Multi-kinase Inhibitor Debio 0617B Reduces Maintenance and Self-renewal of Primary Human AML CD34<sup>+</sup> Stem/Progenitor Cells. *Mol Cancer Ther* 2017; **16**: 1497-1510 [PMID: 28468777 DOI: 10.1158/1535-7163.mct-16-0889]

78 **San-Miguel J**, Bladé J, Shpilberg O, Grosicki S, Maloisel F, Min CK, Polo Zarzuela M, Robak T, Prasad SV, Tee Goh Y, Laubach J, Spencer A, Mateos MV, Palumbo A, Puchalski T, Reddy M, Uhlar C, Qin X, van de Velde H, Xie H, Orlowski RZ. Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti-IL-6) in multiple myeloma. *Blood* 2014; **123**: 4136-4142 [PMID: 24833354 DOI: 10.1182/blood-2013-12-546374]

79 **Brahmer JR**, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, Pitot HC, Hamid O, Bhatia S, Martins R, Eaton K, Chen S, Salay TM, Alaparthy S, Grosso JF, Korman AJ, Parker SM, Agrawal S, Goldberg SM, Pardoll DM, Gupta A, Wigginton JM. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. *N Engl J Med* 2012; **366**: 2455-2465 [PMID: 22658128 DOI: 10.1056/NEJMoa1200694]

80 **Ansell SM**, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M, Schuster SJ, Millenson MM, Cattry D, Freeman GJ, Rodig SJ, Chapuy B, Ligon AH, Zhu L, Grosso JF, Kim SY, Timmerman JM, Shipp MA, Armand P. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. *N Engl J Med* 2015; **372**: 311-319 [PMID: 25482239 DOI: 10.1056/NEJMoa1411087]

81 **Schatton T**, Schütte U, Frank NY, Zhan Q, Hoerning A, Robles SC, Zhou J, Hodi FS, Spagnoli GC, Murphy GF, Frank MH. Modulation of T-cell activation by malignant melanoma initiating cells. *Cancer Res* 2010; **70**: 697-708 [PMID: 20068175 DOI: 10.1158/0008-5472.can-09-1592]

82 **Lanzardo S**, Conti L, Rooke R, Ruiu R, Accart N, Bolli E, Arigoni M, Macagno M, Barrera G, Pizzimenti S, Aurisicchio L, Calogero RA, Cavallo F. Immunotargeting of Antigen xCT Attenuates Stem-like Cell Behavior and Metastatic Progression in Breast Cancer. *Cancer Res* 2016; **76**: 62-72 [PMID: 26567138 DOI: 10.1158/0008-5472.can-15-1208]

83 **Joosse SA**, Pantel K. Tumor-Educated Platelets as Liquid Biopsy in Cancer Patients. *Cancer Cell* 2015; **28**: 552-554 [PMID: 26555171 DOI: 10.1016/j.ccell.2015.10.007]

84 **Yong CSM**, Dardalhon V, Devaud C, Taylor N, Darcy PK, Kershaw MH. CAR T-cell therapy of solid tumors. *Immunol Cell Biol* 2017; **95**: 356-363 [PMID: 28003642 DOI: 10.1038/icb.2016.128]

**P-Reviewer:** Kiselev SLL, Qin JM, Sipos F, Wang L, Xiao Y **S-Editor:** Ji FF **L-Editor: E-Editor:**

**Specialty type:** Cell and tissue engineering

**Country of origin:** Switzerland

**Peer-review report classification**


Grade A (Excellent): 0

Grade B (Very good): B


Grade C (Good): C, C, C, C

Grade D (Fair): 0


Grade E (Poor): 0



**Figure 1 Complex organization of cancer initiation, progress, remission and relapse.** CSCs are capable of undergoing extensive cell proliferation after acquiring different pathologic genetic/epigenetic changes while retaining their stemness and giving rise to differentiated progenies. Acquiring further genetic/epigenetic changes during different stages of tumor progression will evolve CSCs, but this may also be advanced through having dynamic interplay with the stem cell-niche. Both CSCs and non-CSCs can be found at the invasive front of primary tumors, which is linked to the process of EMT. However, only CSCs are capable of surviving from immune-surveillance or conventional tumor therapies and are able to give rise to distance metastasis or cause cancer recurrence. The potential eradication of tumor cells and CSCs can be resulted only upon combination targeted therapeutic approaches. Tumor stem cell-targeting drugs should able to prolong the efficacy of cytotoxic tumor therapy and reduce the recurrence risk. CSC: Cancer stem cell; CC: Cancer cell; NC: Normal cell; EMT: Epithelial-mesenchymal transition.



**Figure 2 Crosstalk between cancer and cancer stem cell-related pathways.** Predicted crosstalk among Wnt signaling, Notch pathway, Hedgehog signaling and other cancer-related pathways like EGF/VEGF signaling in CSCs and cancer. Gene networks and canonical pathways were assessed using the Ariadne Genomics Pathway Studio® program and database (Elsevier). EGF: Epidermal growth factor; VEGF: Vascular endothelial growth factor; WNT: Wnt signaling pathways; PI3K: Phosphoinositide 3-kinase; PIP3: Phosphatidylinositol 3,4,5 trisphosphate; CSC: Cancer stem cell; SHH: Sonic Hedgehog.

****

**Figure 3 Tracing and targeting cancer stem cells.** A: The complex process of distant metastasis including invasion of the tumor microenvironment, EMT, shedding of CSCs into the blood stream (intravasation), MET and invasion of circulating CTCs to the other tissues (extravasation). Only circulating CSCs are able to survive in the circulating blood, escape from immune-surveillance and home to secondary organs; B: The list of known compilation CSC-related molecular markers for different solid tumors and hematopoietic malignancies. The level of specificity of these markers differs per each type of tumor. Markers are ordered alphabetically and not according to their sensitivity or specificity; C: Four important approaches of CSC-targeted therapy. CSC: Cancer stem cell; CC: Cancer cell; NC: Normal cell; EMT: Epithelial-mesenchymal transition; MET: Mesenchymal-epithelial transition; PI3K: Phosphoinositide 3-kinase; MAPK: Mitogen-activated protein kinase; TGF: Transforming growth factor; mTOR: Mechanistic target of rapamycin; RAS: Ras-activated signaling; PD-1: Programmed death 1; PD-L1: Programmed death-ligand 1; EpCAM: Epithelial cell adhesion molecule.

**Table 1 Hallmarks of using cancer stem cell-related markers**

|  |  |
| --- | --- |
| **Problems** | **Potential solutions** |
| CSC-related markers may not be specific by their own for a certain type of tumor | Combined used of different markers may be the solution |
| Some of CSC-related markers may be down-regulated or suppressed in a given tumor due to different genetic or epigenetic regulatory mechanisms | Using of distinct markers or a combination them |
| Splice variants of some CSC-related markers may render detection difficult | The exact splice variant should be considered for the detection |
| Markers can be detected using one method (*e.g.*, FACS), but not with other methods (*e.g*., immunohistochemistry) | Stringent selection of related markers might be required |
| Different tumors have clonal variation and heterogeneous cell population. Less malignant clones may harbor CSCs that express different markers. Therefore, CSC-related markers may be differentially regulated within different clone or be completely missed | Using more specific and sensitive methods, isolate more enriched CSC populations |
| Many of reported CSC-related markers are not validated, since they derived from cell-line or mouse model studies | Markers should be validated in xenotransplants or primary human materials |

CSC: Cancer stem cell; FACS: Fluorescence-activated cell sorting.